MFIM
ESPR

Mesirow Financial Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Mesirow Financial Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$54.8K – 538
2026
Q1 		$54.8K Buy
+20,000
New +$63.3K ﹤0.01% 510
2025
Q4 		– Sell
-20,000
Closed -$53K – 513
2025
Q3 		$53K Hold
20,000
– – ﹤0.01% 547
2025
Q2 		$19.7K Hold
20,000
– – ﹤0.01% 533
2025
Q1 		$28.8K Hold
20,000
– – ﹤0.01% 582
2024
Q4 		$44K Hold
20,000
– – ﹤0.01% 580
2024
Q3 		$33K Hold
20,000
– – ﹤0.01% 584
2024
Q2 		$44.4K Hold
20,000
– – ﹤0.01% 498
2024
Q1 		$53.6K Hold
20,000
– – ﹤0.01% 509
2023
Q4 		$59.8K Buy
+20,000
New +$25.9K ﹤0.01% 543

Other funds holding ESPR

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM

Mesirow Financial Investment Management's ESPR Position: Q2 2026 in Review

Mesirow Financial Investment Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 20,000 shares — an estimated $54.8K sold.

Mesirow Financial Investment Management first reported a position in ESPR in Q4 2023 and held it in 9 quarters. The position peaked at $59.8K in Q4 2023. 41 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Mesirow Financial Investment Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 20,000 Esperion Therapeutics shares in Q2 2026, an estimated $54.8K.
  • Mesirow Financial Investment Management first reported a position in Esperion Therapeutics in Q4 2023 and held it in 9 quarters.
  • Mesirow Financial Investment Management's Esperion Therapeutics position peaked at $59.8K in Q4 2023.
  • 41 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.